MenABCWY

MenABCWY vaccine is currently in preclinical development. The vaccine will combine glycoconjugate antigens (A, C, W and Y) and Neisseria meningitidis group B recombinant proteins with different adjuvants and/or delivery systems.

decrease text sizeincrease text size contact help

About Novartis

About Novartis

We provide medicines to treat and prevent diseases, ease suffering and improve quality of life.

Learn more about our company

News

06 May 2008
First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra*. Novartis expects Menveo to be first quadrivalent meningococcal vaccine to protect from early infancy through adulthood. More than 8 million infants and adolescents in the US and a significant number of children and travellers globally could benefit from Menveo[1]

09 January 2008
Data in JAMA show Menveo may provide infants protection against four of the most common meningococcal serogroups - A, C, W-135 and Y. Menveo stimulates broad immune response against meningococcal disease in infants from two months old

>